Altamira Therapeutics Ltd. (OTCPK: CYTO.F)
Health Care · Pharmaceuticals · BM
$0.06
-8.50% today · -31.9% 1Y
Altamira Therapeutics Ltd. (OTCPK: CYTO.F) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $366.08K and employs 10 people.
Over the last twelve months the share price has lost 31.9%, trading between 0.05 and 0.15.
Tweenvest scores Altamira Therapeutics Ltd. across four factors: quality 27/100. Its strongest factor is quality.
CYTO.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $366.08K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.31
- Dividend yield
- —
- Beta (5Y)
- 2.77
- 52-week high
- $0.15
- 52-week low
- $0.05
- Avg volume (3M)
- —
- Shares outstanding
- 5.72M
- Employees
- 10
- Next earnings
- —
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
- ISIN
- BMG0360L1349
- Founded
- 2003
- Listed since
- Aug 6, 2014
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,256.11 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.93 | +0.63% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.78 | +0.15% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.